Cencora stock enters fiscal 2027 with specialty-led growth outlook

Cencora reported stronger fiscal fourth-quarter results on Wednesday, November 4, after the period ended September 30, 2026. The pharmaceutical solutions company also set a fiscal 2027 outlook that places specialty pharmaceutical and provider services at the center of its growth plan. Its fiscal 2026 results release provides the company figures and outlook.

Cencora stock traded at 309.65 euros on Lang & Schwarz at 13:15 CET on Tuesday, November 10, 2026.

Quarter closes with stronger earnings

Fourth-quarter revenue rose 5.5% from the prior-year quarter to 88.4 billion US dollars. Adjusted diluted earnings per share increased 21.4% to 4.66 US dollars, while adjusted operating income advanced 22.1% to 1.2 billion US dollars. The adjusted figures exclude items such as acquisition-related costs, restructuring expenses, litigation-related items and other specified adjustments.

GAAP diluted earnings per share were 2.71 US dollars, compared with a loss of 1.75 US dollars in the prior-year quarter. The comparison benefited from the absence of a 723.9 million US dollar PharmaLex goodwill impairment charge recorded in the year-earlier period. Cencora also cited higher gross profit, including the contribution from its February 2026 OneOncology acquisition.

For the full fiscal year, revenue rose 5.0% to 337.4 billion US dollars. Adjusted diluted earnings per share increased 12.3% to 17.97 US dollars, and adjusted operating income grew 14.0% to 4.8 billion US dollars.

Specialty segment leads the outlook

Cencora expects fiscal 2027 revenue to grow by 3% to 5% and adjusted operating income by 4% to 6%. Adjusted diluted earnings per share are forecast at 19.40 to 19.75 US dollars, implying growth of 8% to 10% from fiscal 2026. The outlook also assumes a March 31, 2027 closing of the MWI Animal Health merger with Covetrus and the completion of the Profarma stake sale in the first fiscal quarter.

Under the new reporting structure, revenue in Pharmaceutical Distribution and Services is expected to grow by 4% to 6%, with operating income up 2% to 4%. Specialty Pharmaceutical and Provider Services is expected to deliver revenue growth of 9% to 14% and operating income growth of 18% to 21%. That gap makes specialty services the clearest operating growth driver in management's plan, although the business remains exposed to integration, transaction and execution risks.

Capital returns and next milestones

The board declared a quarterly dividend of 0.66 US dollars per common share on November 3, up 10% from 0.60 US dollars. The payment is scheduled for November 30, 2026, to shareholders of record at the close of business on November 13. Management also expects approximately 1.25 billion US dollars of additional share repurchases in fiscal 2027, alongside capital expenditures of about 1.0 billion US dollars and adjusted free cash flow of about 3.5 billion US dollars.

US equities remain the relevant broader market reference for Cencora, with the S&P 500 market overview providing the wider setting.

Management is scheduled to attend the J.P. Morgan Healthcare Conference from January 11 to January 14, 2027. More news and analyses on Cencora stock will track the new segment structure, capital returns and progress toward the fiscal 2027 targets.